NRTIs are faulty versions of building blocks that HIV needs to make more copies of itself. When HIV uses an NRTI instead of a normal building block, reproduction of the virus is stalled. Long term ...
Generally, the dual NRTI backbone treatment of combination with a non-NRTI (NNRTI) or protease inhibitor (PI) should comprise a cytidine analogue (lamivudine, emtricitabine) and a thymidine analogue ...
Cardiomyopathy with Mitochondrial Damage Associated with Nucleoside Reverse-Transcriptase Inhibitors
In July 2000, a 58-year-old man infected with the human immunodeficiency virus (HIV) began treatment with highly active antiretroviral therapy, which initially consisted of zidovudine, lamivudine, and ...
With more than 20 drugs currently licensed to treat HIV infection 1 and over 200 mutations associated with drug resistance 2,3,4,5, it is increasingly difficult to develop a comprehensive ...
Nucleoside reverse transcriptase inhibitors (NRTIs) are linchpins to AIDS therapy, but mitochondrial side effects have increasingly come to light. Mitochondrial DNA (mtDNA) depletion and energy ...
This website will be accessible until September 2025, with all the information being up to date as of July 2024. If you are a supplier, or another partner you can contact our legacy email address as ...
The global reverse transcriptase enzymes industry has witnessed remarkable growth and is anticipated to further expand, reaching a valuation of US$ 335.0 Million in 2022 and projected to escalate to ...
New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.
Clin Drug Invest. 2007;27(8):509-531. Because of its poor tolerability, regimen complexity and drug-interaction potential relative to other new NRTIs, use of didanosine has decreased over the last few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback